MedTrace Logo

Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

NCT02636387 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2022-05-31

No results posted yet for this study

Summary

This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.

Conditions

  • Nocturnal Enuresis
  • Anemia, Sickle Cell

Interventions

DRUG

Desmopressin

Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement

Sponsors & Collaborators

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Kerry A Morrone, MD · Children's Hospital at Montefiore

Eligibility

Min Age
8 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-26
Primary Completion
2018-10-27
Completion
2018-10-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02636387 on ClinicalTrials.gov